• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Hologic showcases new Mammosite at ASTRO 2009

Article

A version of Hologic’s partial breast irradiation device, the MammoSite ML, took center stage this week at the American Society for Therapeutic Radiology and Oncology meeting.

A version of Hologic’s partial breast irradiation device, the MammoSite ML, took center stage this week at the American Society for Therapeutic Radiology and Oncology meeting. The multi-lumen configuration, cleared by the FDA on August 27, allows oncologists to shape the radiation dose. It is the latest enhancement of the basic design, commercially launched some seven years ago. MammoSite delivers targeted radiation therapy directly to the area where cancer is most likely to recur. A full course of radiation can be delivered in just five days. The approach minimizes radiation exposure of healthy tissue surrounding the target site, minimizing side effects such as skin discoloration and scarring, burning, fatigue, and damage to surrounding organs.

Related Videos
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.